Robert Beck, MD
Neurology · Lawrence, KSNPI 1679543649
Payments from drug & device makers
Across 28 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82
- Eisai Inc.$79
- MDD US Operations, LLC$78
- Biogen$57
- Averitas Pharma Inc.$42
- Abbott$35
- plus $250 from 13 others
What the payments were for
- Food & beverage$621100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 4 | $82 |
| Eisai Inc. | 2 | $79 |
| MDD US Operations, LLC | 4 | $78 |
| Biogen | 3 | $57 |
| Averitas Pharma Inc. | 1 | $42 |
| Abbott | 1 | $35 |
| Microtransponder, Inc. | 1 | $33 |
| UCB, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $26 |
| Banner Life Sciences, LLC | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| GE HealthCare | 1 | $20 |
| Amgen | 1 | $18 |
| Argenx US, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $1 |
How this compares
$622 in reported general payments places this provider in the 40th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $124,154 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $86,097 |
| EpidiolexCannabidiol (Cbd) | 11 | $37,623 |
| Nurtec OdtRimegepant Sulfate | 21 | $32,430 |
| Aimovig AutoinjectorErenumab-Aooe | 32 | $23,901 |
| EliquisApixaban | 17 | $17,674 |
| Lacosamide | 51 | $12,323 |
| Dalfampridine ErDalfampridine | 12 | $11,654 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 191 | $8,648 |
| RytaryCarbidopa/Levodopa | 11 | $7,913 |
| Memantine Hcl | 296 | $6,997 |
| Levetiracetam | 272 | $6,193 |
| Aspirin-Dipyridamole ErAspirin/Dipyridamole | 13 | $4,338 |
| DilantinPhenytoin Sodium Extended | 25 | $4,078 |
| Gabapentin | 128 | $3,040 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lawrence
- Ivan OsorioKansas City$101.7M
- Sharon LynchKansas City$9.3M
- Jeffrey BurnsKansas City$6.2M
- Rajesh PahwaKansas City$5M
- Jeffrey KaplanLenexa$4.4M
- Mamatha PasnoorKansas City$3.9M
- Vernon RoweShawnee$1.5M
- William MalloneeHutchinson$1.1M
- Constantine FarmakidisKansas City$649K
- Ricky LeeWichita$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.